Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study. The study focuses on the company’s continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 diabetes. Rutherford, New Jersey-based Glucotrack expects data from the study in 6-8 weeks. Unlike traditional CGMs that measure glucose […]
Glucotrack
Glucotrack survey highlights interest in 3-year continuous blood glucose monitor implant
Glucotrack (Nasdaq:GCTK) today announced findings from a market research study demonstrating the acceptance of its CBGM concept. Rutherford, New Jersey-based Glucotrack develops a small device placed under the skin for continuous blood glucose monitoring. It designed the technology to deliver continuous, accurate blood glucose monitoring for up to three years. This would eliminate some of […]
Focus collaborates with Glucotrack on implantable CBGM
Focus recently announced that it entered into a collaboration with Glucotrack to develop an implantable continuous blood glucose monitor (CBGM). The company said in a LinkedIn post that it expects the long-term, implantable technology to transform how people with diabetes interact with their condition. Focus and Glucotrack want to provide technology that seamlessly integrates into […]
Glucotrack has more data backing implantable glucose monitor, plans for human trials this year
Glucotrack announced the completion of a second long-term preclinical study for its implantable continuous blood glucose monitor (CBGM). The study further validates the CBGM’s sustained accuracy, the company says. It demonstrated a mean absolute relative difference (MARD) — a measurement of CGM accuracy — of 4.7% at day 90. MARD measures the average difference between […]
Glucotrack expands CGM tech to spinal epidural space
Glucotrack (Nasdaq:GCTK) announced today that it plans to expand its glucose monitoring technology to measure glucose in the epidural space. Rutherford, New Jersey-based Glucotrack said CGM taking readings in the spinal epidural space could integrate with existing treatments for painful diabetic neuropathy (PDN). Specifically, Glucotrack sees spinal cord stimulation (SCS) technology as a potential integration […]
Glucotrack has positive data for implantable continuous blood glucose monitor
Glucotrack (Nasdaq:GCK) announced today that it completed the first preclinical study of its implantable continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack aimed to assess the implant technique and device safety in the study. Additionally, the study used a small sample size of sensors to determine device functionality. Despite no intent to conduct an […]
GlucoTrack transitions strategic focus to long-term implantable CGM
Glucotrack (Nasdaq:GCTK) President and CEO Paul V. Goode today issued a statement to shareholders outlining strategic changes. Goode’s letter to shareholders announced a redefined strategic direction. The company wants to move closer to becoming a leader in the diabetes market. According to Goode, the diabetes market has undergone a transformation over recent years. He attributed […]
Glucotrack tabs former Medtronic veteran for a board director spot
Glucotrack (Nasdaq:GCTK) announced today that it appointed Erin Carter to its board of directors, naming her chair of its audit committee. Carter’s appointment comes just days after the implantable continuous glucose monitor (CGM) maker named Drinda Benjamin VP of marketing. She becomes a member of the board and chair of the audit committee, effective immediately. “We […]
Implantable CGM maker Glucotrack names new VP of marketing
Glucotrack (Nasdaq:GCTK) announced that it appointed Drinda Benjamin as its new vice president of marketing. Rutherford, New Jersey-based Glucotrack develops an implantable continuous glucose monitor (CGM). It designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. A recent feasibility study demonstrated reliable glucose measurements for two years post-implant for the device. […]
Feasibility study backs Glucotrack implantable CGM
Glucotrack (Nasdaq:GCK) announced today that it completed a feasibility study for its implantable continuous glucose monitor (CGM). Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. The company said late last year that it planned to expand its product pipeline with an R&D program. The program centers around developing […]
